Impact of Cardiac Computed Tomographic Angiography Findings on Planning of Cancer Therapy in Patients with Concomitant Structural Heart Disease

Abstract EN

Background.

Exclusion of underlying coronary artery disease (CAD) is essential in the diagnosis of chemotherapy-induced cardiomyopathy.

Presence and severity of CAD can also impact the choice of therapy in cancer patients.

The value of cardiac computed tomographic angiography (CCTA) in this setting has not been reported.

Methods.

We collected data on the clinical presentation and indications for CCTA performed from January to December 2008 at the University of Texas MD Anderson Cancer Center (MDACC).

All examinations were performed using a 64-detector scanner.

CCTA results and subsequent treatment decisions were examined.

Results.

A total of 80 patients underwent CCTA during the study period for the following indications (not mutually exclusive): cardiomyopathy of unknown etiology in 33 pts (41.3%), chest pain in 32 (40.0%), abnormal stress test in 16 (20.0%), abnormal cardiac markers in 8 (10.0%), suspected cardiac mass or thrombus in 7 (8.8%).

Chemotherapy-induced cardiomyopathy was diagnosed in 18 pts (22.5%).

Severe CAD was detected in 22 pts (27.5%); due to concomitant advanced cancer or patient refusal, only 12 underwent coronary angiogram.

Of these, 4 pts (5% of total) underwent coronary artery bypass grafting.

A total of 41 pts (51.3%) had their cancer management altered based on CCTA findings.

Conclusion.

CCTA is useful in evaluating cancer pts with structural heart disease and can have an impact on the management of cancer and cardiac disease.